Print

SWOG Selects Sequenta’s LymphoSIGHT™ Platform for Use in 180-Patient Mantle Cell Lymphoma Clinical Trial  
8/6/2012 9:28:56 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. announced today that SWOG has selected Sequenta’s LymphoSIGHT™ platform for the measurement of Minimal Residual Disease (MRD) in a clinical trial.
//-->